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The 4th Global Forum on TB Vaccines, convened in Shanghai, China, from 21 e 24 April 2015, brought
together a wide and diverse community involved in tuberculosis vaccine research and development to
discuss the current status of, and future directions for this critical effort. This paper summarizes the
sessions on Biomarkers and Correlates, and Human Challenge Models. Summaries of all sessions from
the 4th Global Forum are compiled in a special supplement of Tuberculosis. [August 2016, Vol 99, Supp S1,
S1eS30].
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The canonical approach to tuberculosis (TB) vaccine develop-
ment progresses from an idea based on experimental data to
preclinical studies [1]. If protection is consistently observed in all
relevant preclinical studies and has passed all essential gating
criteria, the vaccine can be selected for entering the clinical trial
pipeline. In phase 1 this focuses on obtaining safety and early
immunogenicity data while in phase 2 this includes dosing,
advanced immunogenicity and early efﬁcacy studies. The failure of
a novel TB vaccine candidate to demonstrate protection in a recent
phase 2b efﬁcacy trial [2,3] has raised questions about this
approach, particularly concerning the stringency of the go/no-go
decisions utilized during this process [4]. Application of a more
rigorous gating strategy optimally would lead either to termina-
tion of development efforts for a vaccine candidate prior to an
expensive and resource-intensive phase 2b or phase 3 efﬁcacy trial
or to an iterative approach resulting in opportunities to improvegy, Max Planck Institute for
ny. Fax: þ49 30 28460 501.
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er Ltd. This is an open access articthe vaccine candidate prior to late-stage testing. The identiﬁcation
of biomarkers of protective immunity to Mycobacterium tubercu-
losis (Mtb) infection or TB disease would represent a major step
forward in these efforts to more efﬁciently select vaccine candi-
dates for advancement to late-stage efﬁcacy trials. While the
validation of biomarkers generally requires an efﬁcacy trial of a
successful vaccine, and could rely on either or both immunologic
(antigen-speciﬁc responses) and global gene expression (and other
biomic) proﬁles, it may be possible to identify candidate immune
correlates of protection to guide more efﬁcient vaccine up-
selection via successful non-human primate (NHP) challenge
studies, with subsequent immune bridging between NHPs and
humans. Additionally, biomarkers predictive of risk of TB disease,
obtained from longitudinal studies on Mtb-infected humans who
do or do not develop active TB, would be extraordinarily helpful in
designing clinical studies [5,6]. The development of a human Mtb
challenge model, which would allow early vaccine efﬁcacy as-
sessments in a small group of volunteers, also would represent a
critical advance in the ability to more efﬁciently assess TB vaccine
candidates at an early stage for promotion to late-stage efﬁcacy
studies.
Approaches to identify biomarkers of protection are well un-
derway, and efforts to establish a human Mtb challenge model arele under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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proaches, information from vaccination studies of animals that
naturally acquire TB, such as cattle, also would be helpful in guiding
TB vaccine development efforts. The sessions and presentations on
Biomarkers and Correlates and on the Human Challenge Model
reviewed aspects of these approaches and their potential impor-
tance to future TB vaccine development.
2. Immunodiagnosis of TB disease
TB biomarkers are urgently needed to facilitate and improve
accurate, rapid TB diagnosis at point-of-care settings. Currently,
much diagnostic delay is due to imperfect diagnostic tools for the
early diagnosis of active TB. Prof. Gerhard Walzl (Stellenbosch
University, South Africa) presented his recent work on discovering
diagnostic TB biomarkers, using both antigen-speciﬁc (7-day or
overnight-cultured whole-blood assays) and serum or plasma
responses to differentiate active TB disease from diseases other
than TB. Walzl and colleagues screened 118 different Mtb antigens
for an association with TB in conﬁrmed active pulmonary TB pa-
tients and in healthy household contacts, by assessing their ability
to stimulate interferon-gamma (IFN-g) secretion into the super-
natant of antigen-stimulated cultures analyzed by ELISA. This
investigation demonstrated that TB diagnosis was more accurate
when three to four Mtb antigens were combined (manuscript
submitted). Subsequently, the combination of best performing
antigens was determined in 322 participants with presumptive
TB, and the supernatants of overnight-stimulated cells analyzed
for 42 different cytokines to identify additional markers able to
differentiate between active-TB and no-TB. The result of this effort
was a 6-marker model with 77% sensitivity and 82% speciﬁcity for
diagnosing active TB, which was insufﬁciently informative to
pursue further. Analysis by Quantiferon (QFT) tests of cytokines in
supernatants also proved insufﬁcient for clinical use.
Walzl described ongoing work to identify a panel of circulating
serum markers, since markers of this kind theoretically could be
used directly ex-vivo in a point-of-care setting. From an ambitious
screening of 75 markers obtained from samples from different Af-
rican clinical sites, 10 markers were found to be associated signif-
icantly with TB disease. Using a 6-marker combinatorial approach,
it was possible to reach 88.7% sensitivity and 76.0% speciﬁcity in a
validation cohort. Work is ongoing to establish a 6-marker lateral
ﬂow platform utilizing this strategy for ﬁeld-friendly use.
Walzl concluded his presentation by describing similar studies
on cerebrospinal ﬂuid (CSF) from children with TB meningitis, a
highly fatal form of TB. CSF and serum samples from 146 children
with presumptive TB meningitis were evaluated for 27 pre-
selected markers. A diagnostic model that included three CSF
markers (IL-13, VEGF and cathelicidin LL-37) resulted from this
study. Although the model had only 52% sensitivity and 95%
speciﬁcity, Walzl noted that these results represented a signiﬁcant
improvement over the diagnostic approaches currently available,
therefore representing a potentially valuable test for the diagnosis
of TB meningitis [7].
3. TB candidate vaccine development based on genome-wide
high-throughput screening for immunogens
Prof. Lijun Bi (Institute of Biophysics, Chinese Academy of
Sciences, China) presented a systematic approach to identifying
new Mtb antigens with vaccine and diagnostic potential using a
genome-wide, high-throughput screening strategy for proteina-
ceous immunogens. Bi stated that, because TB subunit vaccine
development is currently based on a few antigens, a more com-
plete picture of the mycobacterial proteome is needed. To achievethis, Bi and colleagues developed a high-throughput system to
express and analyze Mtb proteins. Using the “ORFome approach”
they expressed 95% of the Mtb proteome of H37Rv and CDC1551
(4262 Mtb proteins) in yeast (Saccharomyces cerevisiae) as they
found that a yeast-based expression system yielded better soluble
proteins than the E. coli system. Approximately 90% of Mtb pro-
teins were successfully expressed in a soluble form and were used
to construct a proteome microarray. The applications of this
experimental platform include global studies of proteineprotein
interactions, small moleculeeprotein interactions and TB
biomarker discovery using serum samples. Using their microarray,
Bi and colleagues have selected a panel of 14 candidate
biomarkers which is able to effectively discriminate between pa-
tients with active TB and recovered individuals based on serum
antibodies [8]. They have also screened more than 1000 Mtb
proteins as cellular immunogens using IFN-g release assays. Bi is
currently testing 20 candidate vaccine antigens in a guinea-pig
model. Candidates that show protective immune responses will
be tested further and will enter into clinical trials for vaccine
development.
4. Seeking immune correlates of protection against TB
disease
Dr. Helen Fletcher (London School of Hygiene and Tropical
Medicine-LSTHM, UK) described studies analyzing immune cor-
relates of TB vaccination in relation to protection. She focused on
datasets exploring immune correlates of BCG-mediated protection
in infants in the South African MVA85A trial [2]. A previous study
[9] had demonstrated the lack of predictive potential of classical
Th1/Th17 key markers (IFN-g, TNF-a, IL-2 and IL-17). In this earlier
study, transcriptomics was used to investigate differences between
case and control infants. Although no overarching speciﬁc gene
signature was found, infants were found to cluster into two
distinct immune phenotypes. Cluster 1 was dominated by a strong
IFN-g, IL-2 and TNF phenotype while cluster 2 was dominated by
myeloid and inﬂammatory gene expression patterns with less IFN-
g, IL-2 and TNF. The numbers of TB cases, however, were equally
divided between the two clusters. Despite the opposite trend of T
cell signatures in these two immune phenotype clusters, when the
clusters were stratiﬁed by monocyte/lymphocyte ratios
this correlated with risk of TB disease: cases were found to be
associated with either high or low but not intermediate ratio
determinations.
Transcriptomic analysis of samples from infants from the
MVA85A efﬁcacy study is on-going to determine if this distinct
clustering of infants can be replicated. A series of assays, including
IFN-g ELIspot and cell-surface ﬂow cytometry, have been per-
formed to assess the BCG antigen-speciﬁc response underlying host
immunity using samples from the MVA85A trial to characterize the
immune phenotypes of children that developed TB. The results
further underscore the importance of conducting human clinical
trials given their impact on searching for biomarkers of vaccine
failure and efﬁcacy e a critical aspect of designing improved future
clinical trials.
5. Potential of HLA-E as a novel presentation molecule for
vaccine design against TB
Prof. Tom Ottenhoff (Leiden University Medical Center, the
Netherlands) described a novel type of immune response he and
his colleagues recently discovered in individuals infected with
mycobacteria, including Mtb. This pathway involves presentation
of Mtb antigens to CD8þ T cells via non-classical HLA-E rather than
classical HLA-A,B,C molecules. Compared to HLA-A,B,C, HLA-E
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coding variants), posing a signiﬁcant advantage if utilized in vac-
cine design. Moreover, HLA-E is expressed in the mycobacterial
phagosome, potentially allowing it to play a signiﬁcant role in the
presentation of antigenic Mtb peptides to T-cells.
In contrast to HLA-A, HLA-E is not down-regulated in HIV
infection, such that antigen presentation via HLA-E is likely to be
unaffected by HIV co-infection. Building upon previous work [10],
functional and genetic analyses of HLA-E responses were per-
formed on monoclonal CD8þ T cells. The data showed that HLA-E-
restricted Mtb peptide-speciﬁc CD8þ T-cells displayed unexpected
and unorthodox multi-functionality. CD8þ T-cells stimulated in
this manner were able to kill human target cells infected with BCG
or Mtb and to inhibit intracellular Mtb growth. Yet, they expressed
a characteristic type 2 cytokine proﬁle (IL-4, IL-5, IL-13) and an
ability to help B-cells. Using HLA-E tetramers, Mtb-speciﬁc HLA-E-
restricted CD8þ T-cells were visualized in the circulation of TB
patients [11,12]. Peptide stimulation of these cells again induced
typical type-2 cytokine production. Intriguingly, numbers of HLA-E
tetramer-positive cells decreased in response to TB treatment, in
contrast with the opposite pattern seen for HLA-A2, suggesting
that HLA-E-restricted CD8þ T-cells may make differential contri-
butions to the immunopathogenesis of, and/or protection against
TB disease compared to canonical HLA-A2-restricted CD8þ T-cells.
Thus, the human immune response to Mtb is more diverse than
previously thought, and targeting of the unconventional HLA-E
pathway by new TB vaccines may be a complementary strategy
for TB vaccination.6. Developing a human challenge model for vaccine testing
Development and utilization of a human challenge (HC) model
has signiﬁcantly accelerated vaccine development for a variety of
diseases, including malaria. Prof. Sarah Fortune (Harvard Univer-
sity, USA) introduced the consortium of researchers, supported by
Aeras and the Bill &Melinda Gates Foundation, who have initiated
efforts to develop an HC model for TB vaccine development. The
ﬁrst goal of the TB HC development program is to create attenu-
ated mycobacterial strains that meet pre-clinical safety re-
quirements acceptable for HC studies. As the objective of HC
studies will be to determine whether a test vaccine augments
immune-mediated killing of Mtb, the consortium anticipates that a
vaccine-induced immune effect will be more robust if the HC
strain is capable of replicating, at least brieﬂy, in vivo, independent
of immune control. To build a safe strain capable of only a limited
period of replication, the group is testing several strategies
including establishing nutrient reservoirs in auxotrophs to allow a
period of limited prototrophy, tightly regulated expression of
essential enzymes achieved either through unnatural amino acid-
based regulatory systems or regulated promoters and regulated
expression of self-kill switches.
The HC strain would also have to be detectable in vivo. Fortune
discussed that a pulmonary challenge strain would be more
relevant to a natural Mtb challenge but systemic detection
of bacterial burden would be difﬁcult. Strategies for strain
detection included constructing a strain that either secreted a
detectable small molecule or which could be detected through
endogenous metabolic activity. Creating a strain for a skin chal-
lenge was discussed as an alternative to a pulmonary challenge
strain. Although skin administration might be less biologically
relevant, detection is quite feasible, and safety concerns would be
reduced. Clearly, these efforts are relatively recent and at the next
Global Forum further developments are likely to receive signiﬁ-
cant attention.7. Using the cattle model of bovine tuberculosis to deﬁne
biomarkers of vaccine efﬁcacy or disease progression
Cattle provide an interesting model for studying natural
transmission and assessing TB vaccine candidates. Prof. Martin
Vordermeier (Animal and Plant Health Agency, UK) outlined
some of the challenges in cattle TB research, including difﬁculties
keeping these large animals in BSL3 facilities, the lengthy nature
of infection experiments and the absence of predictive bio-
markers. Bovine TB, caused predominantly by Mycobacterium
bovis, remains a major problem and the BCG vaccine has variable
efﬁcacy against this organism. New vaccine candidates are
available for testing but there is a shortage of BSL3 facilities to
conduct large, costly trials in large animals. He presented ex-
amples of vaccine efﬁcacy studies in cattle after M. bovis chal-
lenge [13,14]. The combination of BCG prime with Ad85A boost
signiﬁcantly reduced overall pathology compared to BCG alone
[13,14]. Vaccinated animals from a typical experiment fell into
two groups: vaccinated/protected and vaccinated/nonprotected.
To identify markers correlated with protection, the outcome of
the challenge (by post-mortem pathological analysis) was
correlated with the type of immune responses pre-challenge.
Examples of hypothesis- and data-driven biomarker discovery
research in this model were presented. An example of the
hypothesis-driven approach was an assessment of vaccine-driven
central memory T-cell generation as a predictor of the outcome
of heterologous prime-boost vaccine strategies, requiring the
application of a cultured IFN-g ELISpot assay [13,15]. This stands
in contrast to the use of the standard, ex vivo ELISpot assay,
which does not speciﬁcally assess central memory T-cell re-
sponses. To characterize the phenotype of bovine memory cells
responsible for these cultured ELISpot responses, T-cell memory
was evaluated by measuring IFN-g-producing cells from both
effector memory T-cells (CD45ROþ, CD62Llo) and central memory
T-cells (CD45ROþ, CD62Lhi). These cells were isolated from PBMC
and cultured for 12e14 days with antigen and regular addition of
IL-2, after which the expanded cells were used in the ELISpot.
The results showed that in the short term, ex-vivo ELISpot central
and effector memory/effector T-cells contributed almost equally
to the production of IFN-g while in the cultured ELISpot,
approximately 70% of IFN-g-producing cells expressed a central
memory phenotype. The cultured ELISpot assay at the time of
challenge thus correlated with vaccine performance. An example
of a data-driven approach was transcriptomics, where data were
shown suggesting correlation of IL-17 and IL-22 expression with
vaccine efﬁcacy [16]. The main source of IL-17 and IL-22 was from
CD4þ and gd T-cells (in cattle, gd T-cells represent a more
prominent T lymphocyte population than in humans). The cattle
model can productively complement similar research efforts in
humans and other experimental animal models.
8. Conclusion
The summarized presentations addressed a wide range of issues
critical to the development of new TB vaccine candidates. Devel-
opment of more sensitive and speciﬁc diagnostics for Mtb infection
and TB disease may open up opportunities for new pathways to
vaccine evaluation. High throughput, genomic screening for TB
immunogens, and exploration of non-classical pathways of TB an-
tigen presentation, such as the HLA-E pathway, offer the potential
for the rational development of new vaccine candidates that could
stand alone or complement vaccines currently being studied.
Identiﬁcation of immunological correlates of immune protection
would prove invaluable to TB vaccine testing regimens, as would
the development of an HC model of TB, as witnessed by the
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for this disease [17]. Developing such tools would provide essential
information for early, rational go/no-go vaccine development de-
cisions, and guide the way forward towards designing more effec-
tive TB vaccines, including the activation of novel unconventional
immunity. Ultimately, biological samples from ongoing vaccine
trials will be needed and information from their analyses must be
made available to the broader vaccine community to facilitate
iterative, rational and efﬁcient vaccine design; vaccine selection
based on comparative performance evaluation; and commitment
towards further clinical development [4].
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